These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

507 related articles for article (PubMed ID: 31332617)

  • 81. Analysis of CAR-Mediated Tonic Signaling.
    Calderon H; Mamonkin M; Guedan S
    Methods Mol Biol; 2020; 2086():223-236. PubMed ID: 31707680
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Gene modification strategies for next-generation CAR T cells against solid cancers.
    Tian Y; Li Y; Shao Y; Zhang Y
    J Hematol Oncol; 2020 May; 13(1):54. PubMed ID: 32423475
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Applications and Opportunities for Immune Cell CAR Engineering in Comparative Oncology.
    Rotolo A; Atherton MJ
    Clin Cancer Res; 2024 Jun; 30(11):2359-2369. PubMed ID: 38573683
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Chimeric Antigen Receptor-Engineered T Cell Therapy for the Management of Patients with Metastatic Prostate Cancer: A Comprehensive Review.
    Yu YD; Kim TJ
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33440664
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management.
    Brudno JN; Kochenderfer JN
    Blood Rev; 2019 Mar; 34():45-55. PubMed ID: 30528964
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities.
    Shum T; Kruse RL; Rooney CM
    Expert Opin Biol Ther; 2018 Jun; 18(6):653-664. PubMed ID: 29727246
    [TBL] [Abstract][Full Text] [Related]  

  • 87. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
    Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
    J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Designing chimeric antigen receptors to effectively and safely target tumors.
    Jensen MC; Riddell SR
    Curr Opin Immunol; 2015 Apr; 33():9-15. PubMed ID: 25621840
    [TBL] [Abstract][Full Text] [Related]  

  • 89. CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia.
    Singh N; Frey NV; Grupp SA; Maude SL
    Curr Treat Options Oncol; 2016 Jun; 17(6):28. PubMed ID: 27098534
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Chimeric Antigen Receptor T-Cell Therapy in Lung Cancer: Potential and Challenges.
    Xiao BF; Zhang JT; Zhu YG; Cui XR; Lu ZM; Yu BT; Wu N
    Front Immunol; 2021; 12():782775. PubMed ID: 34790207
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Preclinical Assessment of CAR T-Cell Therapy Targeting the Tumor Antigen 5T4 in Ovarian Cancer.
    Owens GL; Sheard VE; Kalaitsidou M; Blount D; Lad Y; Cheadle EJ; Edmondson RJ; Kooner G; Gilham DE; Harrop R
    J Immunother; 2018 Apr; 41(3):130-140. PubMed ID: 29239915
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase.
    Walker AJ; Majzner RG; Zhang L; Wanhainen K; Long AH; Nguyen SM; Lopomo P; Vigny M; Fry TJ; Orentas RJ; Mackall CL
    Mol Ther; 2017 Sep; 25(9):2189-2201. PubMed ID: 28676342
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Engineering CAR-T Cells for Improved Function Against Solid Tumors.
    Morgan MA; Schambach A
    Front Immunol; 2018; 9():2493. PubMed ID: 30420856
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Determination of Cytotoxic Potential of CAR-T Cells in Co-cultivation Assays.
    Nacasaki Silvestre R; Moço PD; Picanço-Castro V
    Methods Mol Biol; 2020; 2086():213-222. PubMed ID: 31707679
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors.
    Zhang BL; Qin DY; Mo ZM; Li Y; Wei W; Wang YS; Wang W; Wei YQ
    Sci China Life Sci; 2016 Apr; 59(4):340-8. PubMed ID: 26965525
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Mechanisms of response and resistance to CAR T cell therapies.
    Berger TR; Maus MV
    Curr Opin Immunol; 2021 Apr; 69():56-64. PubMed ID: 33752101
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Antagonism of IAPs Enhances CAR T-cell Efficacy.
    Michie J; Beavis PA; Freeman AJ; Vervoort SJ; Ramsbottom KM; Narasimhan V; Lelliott EJ; Lalaoui N; Ramsay RG; Johnstone RW; Silke J; Darcy PK; Voskoboinik I; Kearney CJ; Oliaro J
    Cancer Immunol Res; 2019 Feb; 7(2):183-192. PubMed ID: 30651288
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Generation of CAR-T Cells for Cancer Immunotherapy.
    Xu Q; Harto H; Berahovich R; Xu S; Zhou H; Golubovskaya V; Wu L
    Methods Mol Biol; 2019; 1884():349-360. PubMed ID: 30465215
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Development of a novel target module redirecting UniCAR T cells to Sialyl Tn-expressing tumor cells.
    Loureiro LR; Feldmann A; Bergmann R; Koristka S; Berndt N; Arndt C; Pietzsch J; Novo C; Videira P; Bachmann M
    Blood Cancer J; 2018 Aug; 8(9):81. PubMed ID: 30190468
    [No Abstract]   [Full Text] [Related]  

  • 100. Chimeric antigen receptor T-cell therapy for cancer: a basic research-oriented perspective.
    Han C; Kwon BS
    Immunotherapy; 2018 Mar; 10(3):221-234. PubMed ID: 29370727
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.